Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model

• Published in: Veterinary & comparative oncology 2017-09, Vol.15 (3), p.754-763
• Main Authors: Frazier, J. P., Beirne, E., Ditzler, S. H., Tretyak, I., Casalini, J. R., Thirstrup, D. J., Knoblaugh, S., Ward, J. G., Tripp, C. D., Klinghoffer, R. A.
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor; comparative oncology; Disease Models, Animal; Dogs; Heterografts; in vitro models; Male; Mice; Mice, Nude; mouse models; Neoplasm Transplantation - methods; Neoplasm Transplantation - veterinary; oncology; pathology; Sarcoma - drug therapy; Sarcoma - pathology; Sarcoma - veterinary; Sarcoma, Experimental - drug therapy; Sarcoma, Experimental - pathology; tumor biology
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12215

Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STSs are a valuable and readily available resource for the study of new therapeutics. In this study, a canine patient‐derived xenograft (PDX) model, CDX‐STS2, was established. The CDX‐STS2 model was engrafted and expanded for systemic administration studies with chemotherapeutic agents commonly used to treat STS, including doxorubicin, docetaxel and gemcitabine. Immunohistochemistry for drug‐specific biomarkers and tumour growth measurement revealed tumour sensitivity to doxorubicin and docetaxel, whereas gemcitabine had no effect on tumour growth. Although many human PDX tumour models have been established, relatively few canine PDX models have been reported to date. CDX‐STS2 represents a new STS PDX research model of canine origin that will be useful in bridging preclinical research with clinical studies of STS in pet dogs.